DekaBank Deutsche Girozentrale Lowers Holdings in Johnson & Johnson (JNJ)

DekaBank Deutsche Girozentrale lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,596,500 shares of the company’s stock after selling 21,183 shares during the period. Johnson & Johnson comprises 1.4% of DekaBank Deutsche Girozentrale’s investment portfolio, making the stock its 7th biggest holding. DekaBank Deutsche Girozentrale’s holdings in Johnson & Johnson were worth $205,036,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. NuWave Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $680,000. IBM Retirement Fund lifted its position in shares of Johnson & Johnson by 4.8% during the 4th quarter. IBM Retirement Fund now owns 70,094 shares of the company’s stock worth $10,697,000 after buying an additional 3,221 shares during the last quarter. Keeler Thomas Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $2,692,000. OxFORD Asset Management LLP lifted its position in shares of Johnson & Johnson by 407.9% during the 3rd quarter. OxFORD Asset Management LLP now owns 27,431 shares of the company’s stock worth $3,561,000 after buying an additional 22,030 shares during the last quarter. Finally, Hefty Wealth Partners lifted its position in shares of Johnson & Johnson by 959.3% during the 4th quarter. Hefty Wealth Partners now owns 6,970 shares of the company’s stock worth $974,000 after buying an additional 6,312 shares during the last quarter. Institutional investors own 65.97% of the company’s stock.

JNJ has been the subject of several recent analyst reports. Jefferies Financial Group set a $161.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, March 23rd. Vetr downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price objective for the company. in a research report on Monday, March 26th. TheStreet downgraded shares of Johnson & Johnson from an “a” rating to a “c+” rating in a research report on Monday, March 26th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 price target for the company in a research report on Wednesday, March 28th. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 10th. Six analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $141.60.

Shares of Johnson & Johnson stock opened at $121.58 on Tuesday. The firm has a market cap of $325.54 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 1.86 and a beta of 0.74. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. Johnson & Johnson’s quarterly revenue was up 12.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.83 EPS. equities research analysts forecast that Johnson & Johnson will post 8.13 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th were given a dividend of $0.90 per share. The ex-dividend date of this dividend was Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.96%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply